The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets

Antioxidants and Redox Signaling

Volumn 15, Issue 9, 2011, Pages 2439-2453

  Venè, Roberta ^a   Castellani, Patrizia ^a   Delfino, Laura ^a   Lucibello, Maria ^b   Ciriolo, Maria Rosa ^c,d   Rubartelli, Anna ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYPHENYLGLYCINE; ANTIOXIDANT; BUTHIONINE SULFOXIMINE; CYSTEINE; CYSTINE; GLUTATHIONE; SELENITE; THIOREDOXIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL; OXIDATION REDUCTION REACTION; PHENOTYPE; PRIORITY JOURNAL;

ANTIOXIDANTS; ARSENICALS; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CELL SURVIVAL; CYSTEINE; CYSTINE; GLUTATHIONE; GLYCINE; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; OXIDATION-REDUCTION; OXIDES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 80053037896     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3830     Document Type: Article

References (58)

1. Anderson CL, Iyer SS, Ziegler TR, and Jones DP. Control of extracellular cysteine/cystine redox state by HT-29 cells is independent of cellular glutathione. Am J Physiol Regul Integr Comp Physiol 293: R1069-1075, 2007. (Pubitemid 47358926)
2. Angelini G, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, Clarke F, Sitia R, and Rubartelli A. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 99: 1491-1496, 2002. (Pubitemid 34136520)
3. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kölle P, Tschoep K, Issels RD, Daniel PT, Conrad M, and Bornkamm GW. The cystine/cysteine cycle: A redox cycle regulating susceptibility versus resistance to cell death. Oncogene 27: 1618-1628, 2008. (Pubitemid 351347880)
4. Cabello CM, Bair WB 3rd, and Wondrak GT. Experimental therapeutics: Targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 8: 1022-1037, 2007. (Pubitemid 350224328)
5. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L, and Ferlazzo G. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 4: e8132, 2009.
6. Carta S, Castellani P, Delfino L, Tassi S, Venè R, and Rubartelli A. DAMPs and inflammatory processes: The role of redox in the different outcomes. J Leukoc Biol 86: 549-555, 2009.
7. Ceccarelli J, Delfino L, Zappia E, Castellani P, Borghi M, Ferrini S, Tosetti F, and Rubartelli A. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer 123: 1770-1778, 2008.
8. Chaiswing L and Oberley TD. Extracellular/microenvironmental redox state Antioxid Redox Signal 13: 449-465, 2010.
9. Chang Q, Pan J, Wang X, Zhang Z, Chen F, and Shi X. Reduced reactive oxygen species-generating capacity contributes to the enhanced cell growth of arsenic-transformed epithelial cells. Cancer Res 70: 5127-5135, 2010.
10. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, Guo XL, Dong LJ, He X, Qiao HX, and Zhan QM, and Li W. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 28: 599-609, 2009.
11. Chung WJ and Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem. 110: 182-193, 2009.
12. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, and Wang YZ. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67: 162-171, 2007. (Pubitemid 46185319)
13. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002. (Pubitemid 34654215)
14. Frank J, Lornejad-Schafer MR, Schoffl H, Flaccus A, Lambert C, and Biesalski HK. Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy. Int J Oncol 31: 1539-1545, 2007.
15. Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, Pompella A, and Zunino F. Gamma-glutamyltransferasedependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid. Free Radic Biol Med 46: 1516-1526, 2009.
16. Grek CL and Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol 10: 362-368, 2010.
17. Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704-13712, 1982. (Pubitemid 13187133)
18. Huang Y, Dai Z, Barbacioru C, and Sadée W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65: 7446-7454, 2005. (Pubitemid 41161279)
19. Hussain SP, Hofseth LJ, and Harris CC. Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003. (Pubitemid 37328863)
20. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, and Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19: 387-400, 2011.
21. Ivanov VN and Hei TK. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem 279: 22747-22758, 2004. (Pubitemid 38679475)
22. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, and Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486-5496, 2010.
23. Kalinina EV, Chernov NN, and Saprin AN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc) 73: 1493-1510, 2008.
24. Landriscina M, Maddalena F, Laudiero G, and Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 11: 2701-2716, 2009.
25. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, and Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100: 773-783, 2008. (Pubitemid 351809666)
26. Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, and Magda D. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 65: 11676-11688, 2005. (Pubitemid 41821728)
27. Lesiak K, Koprowska K, Zalesna I, Nejc D, Dü chler M, and Czyz M. Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. Melanoma Res 20: 21-34, 2010.
28. Lillig CH and Holmgren A. Thioredoxin and related molecules: From biology to health and disease. Antioxid Redox Signal 9: 25-47, 2007. (Pubitemid 44901873)
29. Lo M, Ling V, Wang YZ, and Gout PW. The xc-cystine/glutamate antiporter: A mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99: 464-472, 2008.
30. Lo M, Wang YZ, and Gout PW. The x(c)-cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 215: 593-602, 2008. (Pubitemid 351632680)
31. Lo M, Ling V, Low C, Wang YZ, and Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol. 17: 9-16, 2010.
32. Mandal PK, Seiler A, Perisic T, Kö lle P, Banjac Canak A, Fö rster H, Weiss N, Kremmer E, Lieberman MW, Bannai S, Kuhlencordt P, Sato H, Bornkamm GW, and Conrad M. System x(c)-and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J Biol Chem 285: 22244-22253, 2010.
33. Massrieh W, Derjuga A and Blank V. Induction of endogenous Nrf2/Small Maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells Antioxid Redox Signal 8: 53-59, 2006 (Pubitemid 43324530)
34. Meister A. Glutathione metabolism. Methods Enzymol 251: 3-7, 1995.
35. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, and Khayat D. Treatment for metastatic malignant melanoma: Old drugs and new strategies. Crit Rev Oncol Hematol 74: 27-39, 2010.
36. Narang VS, Pauletti GM, Gout PW, Buckley DJ, and Buckley AR. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: Enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy 53: 210-217, 2007. (Pubitemid 46581995)
37. Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, and Bannai S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer 88: 951-956, 2003. (Pubitemid 36520886)
38. Olm E, Fernandes AP, Hebert C, Rundlö f AK, Larsen EH, Danielsson O, and Bjö rnstedt M. Extracellular thiol-assisted selenium uptake dependent on the x(c)-cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci USA 106: 11400-11405, 2009.
39. Powis G and Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7: 392-397, 2007. (Pubitemid 47289261)
40. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, and Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460, 2005. (Pubitemid 41330613)
41. Rubartelli A and Lotze MT. Inside, outside, upside down: Damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28: 429-436, 2007. (Pubitemid 47444554)
42. Sato H, Tamba M, and Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274:11455-11458, 1999.
43. Semino C, Angelini G, Poggi A, and Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106: 609-616, 2005. (Pubitemid 40981258)
44. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, and Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
45. Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, and Bernstein SH. Modulation of cell surface protein free thiols: A potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 4: e8115, 2009.
46. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Sä ily M, Koistinen P, Pääakkö P, Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001. (Pubitemid 32708645)
47. Tang D, Kang R, Zeh HJ, and Lotze MT. HMGB1, oxidative stress, and disease. Antioxid Redox Signal, 14: 1315-1335, 2010.
48. Tassi S, Carta S, Delfino L, Corsi R, Martini A, Gattorno M, and Rubartelli A. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci USA 107: 9789-9794, 2010.
49. Tassi S, Carta S, Vené R, Delfino L, Ciriolo MR, and Rubartelli A. Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response. J Immunol 183: 1456-1462, 2009.
50. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006. (Pubitemid 44311067)
51. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007. (Pubitemid 44566469)
52. Vené R, Delfino L, Castellani P, Balza E, Bertolotti M, Sitia R, and Rubartelli A. Redox remodeling allows and controls Bcell activation and differentiation. Antioxid Redox Signal 13: 1145-1155, 2010.
53. Venè R, Larghero P, Arena G, Sporn MB, Albini A, and Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res 68: 6987-6996, 2008.
54. Wang J and Yi J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol Ther 7: 1875-1884, 2008.
55. Wittgen HG and van Kempen LC, Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 17: 400-409, 2007. (Pubitemid 350084996)
56. Wondrak GT. Redox-directed cancer therapeutics: Molecular mechanisms and 0pportunities. Antioxid Redox Signal 11: 3013-3069, 2009.
57. Yan Z, Garg SK, and Banerjee R. Extracellular redox modulation by regulatory T cells. Nat Chem Biol 5: 721-723, 2009.
58. Yang P, Ebbert JO, Sun Z, and Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review. J Clin Oncol 24: 1761-1769, 2006. (Pubitemid 46622148)